Log in
NASDAQ:FOLD

Amicus Therapeutics Competitors

$23.24
+0.48 (+2.11 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$22.51
Now: $23.24
$23.26
50-Day Range
$14.90
MA: $19.38
$22.76
52-Week Range
$6.25
Now: $23.24
$23.26
Volume1.63 million shs
Average Volume2.77 million shs
Market Capitalization$6.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47

Competitors

Amicus Therapeutics (NASDAQ:FOLD) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying FOLD stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Amicus Therapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Amgen and Amicus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Amicus Therapeutics-129.10%-65.53%-36.94%

Institutional and Insider Ownership

71.7% of Amgen shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Amgen and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.60$7.84 billion$14.8215.17
Amicus Therapeutics$182.24 million33.23$-356,390,000.00($1.31)-17.74

Amgen has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Amgen has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Amgen and Amicus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
Amicus Therapeutics02802.80

Amgen currently has a consensus price target of $254.08, suggesting a potential upside of 13.02%. Amicus Therapeutics has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Given Amgen's higher probable upside, research analysts clearly believe Amgen is more favorable than Amicus Therapeutics.

Summary

Amgen beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Gilead Sciences and Amicus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Amicus Therapeutics-129.10%-65.53%-36.94%

Institutional and Insider Ownership

77.9% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Gilead Sciences and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.35$5.39 billion$6.149.78
Amicus Therapeutics$182.24 million33.23$-356,390,000.00($1.31)-17.74

Gilead Sciences has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gilead Sciences has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Gilead Sciences and Amicus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151002.30
Amicus Therapeutics02802.80

Gilead Sciences currently has a consensus price target of $76.1538, suggesting a potential upside of 26.86%. Amicus Therapeutics has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Given Gilead Sciences' higher probable upside, research analysts clearly believe Gilead Sciences is more favorable than Amicus Therapeutics.

Summary

Gilead Sciences beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Vertex Pharmaceuticals and Amicus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Amicus Therapeutics-129.10%-65.53%-36.94%

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion14.16$1.18 billion$4.2952.85
Amicus Therapeutics$182.24 million33.23$-356,390,000.00($1.31)-17.74

Vertex Pharmaceuticals has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Vertex Pharmaceuticals and Amicus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals082212.77
Amicus Therapeutics02802.80

Vertex Pharmaceuticals currently has a consensus price target of $290.5862, suggesting a potential upside of 28.18%. Amicus Therapeutics has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Given Vertex Pharmaceuticals' higher probable upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Amicus Therapeutics.

Summary

Vertex Pharmaceuticals beats Amicus Therapeutics on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Regeneron Pharmaceuticals and Amicus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals37.30%26.71%19.39%
Amicus Therapeutics-129.10%-65.53%-36.94%

Institutional and Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.98$2.12 billion$21.4723.94
Amicus Therapeutics$182.24 million33.23$-356,390,000.00($1.31)-17.74

Regeneron Pharmaceuticals has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Regeneron Pharmaceuticals and Amicus Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0101312.63
Amicus Therapeutics02802.80

Regeneron Pharmaceuticals currently has a consensus price target of $628.52, suggesting a potential upside of 22.27%. Amicus Therapeutics has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Given Regeneron Pharmaceuticals' higher probable upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amicus Therapeutics.

Summary

Regeneron Pharmaceuticals beats Amicus Therapeutics on 12 of the 15 factors compared between the two stocks.

Amicus Therapeutics (NASDAQ:FOLD) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Amicus Therapeutics and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amicus Therapeutics02802.80
Biogen5151302.24

Amicus Therapeutics currently has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Biogen has a consensus price target of $305.9032, suggesting a potential upside of 25.48%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Amicus Therapeutics.

Profitability

This table compares Amicus Therapeutics and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amicus Therapeutics-129.10%-65.53%-36.94%
Biogen35.63%51.00%23.54%

Institutional & Insider Ownership

78.9% of Biogen shares are owned by institutional investors. 2.5% of Amicus Therapeutics shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Amicus Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Valuation and Earnings

This table compares Amicus Therapeutics and Biogen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$182.24 million33.23$-356,390,000.00($1.31)-17.74
Biogen$14.38 billion2.61$5.89 billion$33.577.26

Biogen has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

Amicus Therapeutics (NASDAQ:FOLD) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Amicus Therapeutics and Seagen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amicus Therapeutics02802.80
Seagen161112.63

Amicus Therapeutics currently has a consensus price target of $21.35, suggesting a potential downside of 8.13%. Seagen has a consensus price target of $176.75, suggesting a potential upside of 4.51%. Given Seagen's higher probable upside, analysts plainly believe Seagen is more favorable than Amicus Therapeutics.

Profitability

This table compares Amicus Therapeutics and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amicus Therapeutics-129.10%-65.53%-36.94%
Seagen-25.17%-18.32%-15.49%

Institutional & Insider Ownership

92.0% of Seagen shares are owned by institutional investors. 2.5% of Amicus Therapeutics shares are owned by insiders. Comparatively, 31.1% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Amicus Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amicus Therapeutics and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$182.24 million33.23$-356,390,000.00($1.31)-17.74
Seagen$916.71 million33.26$-158,650,000.00($1.33)-127.16

Seagen has higher revenue and earnings than Amicus Therapeutics. Seagen is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Amicus Therapeutics on 11 of the 15 factors compared between the two stocks.


Amicus Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$224.81+2.0%$130.88 billion$23.36 billion18.13Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.9$60.03+0.9%$75.25 billion$22.45 billion61.89Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$226.71+3.8%$58.95 billion$4.16 billion28.63
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$514.05+1.1%$54.85 billion$7.86 billion19.90
Biogen logo
BIIB
Biogen
2.0$243.78+0.8%$37.51 billion$14.38 billion8.07Analyst Revision
Seagen logo
SGEN
Seagen
1.4$169.12+2.2%$30.49 billion$916.71 million-112.00Analyst Downgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.0$123.83+0.7%$27.10 billion$4.99 billion28.93
Incyte logo
INCY
Incyte
1.5$83.25+2.5%$18.23 billion$2.16 billion-53.03
Exact Sciences logo
EXAS
Exact Sciences
1.6$118.19+2.0%$17.78 billion$876.29 million-53.48
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$129.86+3.4%$15.09 billion$219.75 million-16.58Analyst Report
Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$80.40+2.8%$14.60 billion$1.70 billion18.40
Repligen logo
RGEN
Repligen
1.4$186.99+3.0%$9.84 billion$270.24 million322.40
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.56+0.5%$8.93 billion$788.10 million45.29Analyst Downgrade
Novavax logo
NVAX
Novavax
1.8$125.69+18.4%$8.00 billion$18.66 million-45.71
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$51.13+1.7%$7.15 billion$1.12 billion106.52Insider Selling
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.54+0.3%$6.02 billion$1.45 billion13.92
Exelixis logo
EXEL
Exelixis
1.9$19.41+3.5%$6.02 billion$967.78 million40.44Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.23+2.3%$5.44 billion$195.99 million251.44Analyst Report
Insider Selling
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$82.83+2.9%$4.39 billion$1.11 billion26.63
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$55.81+3.2%$3.86 billion$36.13 million-83.30
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+0.6%$3.83 billion$806.43 million-9.33
Alkermes logo
ALKS
Alkermes
1.3$18.50+0.4%$2.94 billion$1.17 billion-40.22
OPKO Health logo
OPK
OPKO Health
1.9$4.13+4.4%$2.77 billion$901.90 million-12.51
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.83+1.7%$1.89 billion$428.41 million17.14
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$119.11+6.0%$1.84 billionN/A-10.76
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$10.12+3.5%$1.43 billion$102.43 million-12.19
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$85.92+1.7%$1.38 billion$120.28 million-86.79
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$17.78+2.4%$1.34 billion$638.60 million-6.63
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$37.27+0.3%$1.23 billion$252 million-3.60
Innoviva logo
INVA
Innoviva
1.1$10.85+2.7%$1.10 billion$261.02 million5.54
Codexis logo
CDXS
Codexis
1.1$18.01+0.8%$1.07 billion$68.46 million-51.46
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.52+4.0%$1.04 billion$82.27 million-12.84Analyst Upgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$5.13+7.2%$905.78 million$48.83 million-6.75
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$22.75+4.4%$900.15 million$3.57 million-10.20
MannKind logo
MNKD
MannKind
0.9$3.08+4.2%$716.41 million$63.04 million-14.67
Agenus logo
AGEN
Agenus
1.6$3.71+5.4%$705.45 million$150.05 million-3.40
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.73+3.6%$690.21 million$109.33 million-3.88
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.2$12.41+2.4%$678.73 million$227.19 million5.94Analyst Downgrade
Heavy News Reporting
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.50+0.1%$650.03 million$38.19 million37.50
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.91+0.3%$623.59 million$150,000.00-4.16
Geron logo
GERN
Geron
1.4$1.87+3.2%$580.58 million$460,000.00-5.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.79+11.3%$527.73 million$35.22 million-3.50
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.11+5.8%$525.53 million$59.29 million-22.21
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75+0.0%$477.47 million$327.75 million-1.89
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.12+3.1%$455.67 million$22.27 million-4.47
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.76+6.7%$420.40 million$143.01 million-0.91
XOMA logo
XOMA
XOMA
1.4$32.05+1.9%$353.26 million$18.37 million-28.87Analyst Report
Insider Selling
Verastem logo
VSTM
Verastem
1.5$1.99+14.6%$337.85 million$17.46 million-1.41High Trading Volume
Unusual Options Activity
Heavy News Reporting
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.59+1.2%$295.85 million$54.76 million-1.95
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$2.77+5.8%$259.56 million$36.63 million-3.18
This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.